Speaker(s): 

Sara Gaines, Pharm D, MTM Hepatology Pharmacist - has nothing to disclose.

Moderator(s): 

Lorella Thomas, CRNP, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Apply evidence‑based noninvasive fibrosis assessment tools to risk‑stratify patients in clinical practice
• Differentiate among current lifestyle, pharmacologic, and interventional treatment options for MASH based on patient‑specific metabolic and hepatic risk profiles

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Karla Leschinsky, PA-C; Briget Stem, RN; Alyssa Bertram, PharmD and Lorella Thomas, CRNP have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None